Atorvastatin inhibits collar-induced intimal thickening of rat carotid artery: Effect on C-type natriuretic peptide expression

Molecular Medicine Reports

Volumn 5, Issue 3, 2012, Pages 675-679

  Li, Yongjie ^a   Gao, Yuan ^a   Zeng, Dingyin ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Atherosclerosis; Atorvastatin; C type natriuretic peptide; Cyclic guanosine monophosphate dependent protein kinase; Intimal thickening; Peri arterial collar

Indexed keywords

ATORVASTATIN; CYCLIC GMP DEPENDENT PROTEIN KINASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; NATRIURETIC PEPTIDE TYPE C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY; COMPETITIVE INHIBITION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; MALE; NEOINTIMA; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CAROTID ARTERY INJURIES; CYCLIC GMP-DEPENDENT PROTEIN KINASES; GENE EXPRESSION REGULATION; HEPTANOIC ACIDS; MALE; NATRIURETIC PEPTIDE, C-TYPE; NEOINTIMA; PYRROLES; RATS;

AMBYSTOMA TIGRINUM STEBBENSI VIRUS; RATTUS;

EID: 84863057718     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.698     Document Type: Article

References (33)

1. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 340: 115-126, 1999.
2. Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352: 1685-1695, 2005.
3. Rocha VZ and Libby P: Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol 6: 399-409, 2009.
4. Nissen SE, Nicholls SJ, Sipahi I, et al: Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295: 1556-1565, 2006.
5. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389, 1994.
6. Shepherd J, Cobbe SM, Ford I, et al: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group. N Engl J Med 333: 1301-1307, 1995.
7. Sacks FM, Pfeffer MA, Moye LA, et al: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 335: 1001-1009, 1996. (Pubitemid 26338729)
8. Heart Protection Study Collaborative Group: MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 7-22, 2002.
9. Hebert PR, Gaziano JM, Chan KS and Hennekens CH: Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 278: 313-321, 1997. (Pubitemid 27339660)
10. Maron DJ, Fazio S and Linton MF: Current perspectives on statins. Circulation 101: 207-213, 2000. (Pubitemid 30044262)
11. Ridker PM, Danielson E, Fonseca FA, et al: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359: 2195-2207, 2008.
12. Albert MA, Danielson E, Rifai N and Ridker PM: Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 286: 64-70, 2001. (Pubitemid 32606333)
13. Kinlay S, Schwartz GG, Olsson AG, et al: High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 108: 1560-1566, 2003. (Pubitemid 37187781)
14. Scotland RS, Ahluwalia A and Hobbs AJ: C-type natriuretic peptide in vascular physiology and disease. Pharmacol Ther 105: 85-93, 2005.
15. Ahluwalia A and Hobbs AJ: Endothelium-derived C-type natriuretic peptide: more than just a hyperpolarizing factor. Trends Pharmacol Sci 26: 162-167, 2005. (Pubitemid 40313596)
16. Murakami S, Nagaya N, Itoh T, et al: C-type natriuretic peptide attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 287: L1172-L1177, 2004. (Pubitemid 39507194)
17. Scotland RS, Cohen M, Foster P, et al: C-type natriuretic peptide inhibits leukocyte recruitment and platelet-leukocyte interactions via suppression of P-selectin expression. Proc Natl Acad Sci USA 102: 14452-14457, 2005. (Pubitemid 41429718)
18. Shinomiya M, Tashiro J, Saito Y, et al: C-type natriuretic peptide inhibits intimal thickening of rabbit carotid artery after balloon catheter injury. Biochem Biophys Res Commun 205: 1051-1056, 1994.
19. Ueno H, Haruno A, Morisaki N, et al: Local expression of C-type natriuretic peptide markedly suppresses neointimal formation in rat injured arteries through an autocrine/paracrine loop. Circulation 96: 2272-2279, 1997. (Pubitemid 27425833)
20. Doi K, Ikeda T, Itoh H, et al: C-type natriuretic peptide induces redifferentiation of vascular smooth muscle cells with accelerated reendothelialization. Arterioscler Thromb Vasc Biol 21: 930-936, 2001. (Pubitemid 34168648)
21. Casco VH, Veinot JP, Kuroski de Bold ML, Masters RG, Stevenson MM and de Bold AJ: Natriuretic peptide system gene expression in human coronary arteries. J Histochem Cytochem 50: 799-809, 2002. (Pubitemid 34721448)
22. Barrios V, Amabile N, Paganelli F, et al: Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. Int J Clin Pract 59: 1377-1386, 2005. (Pubitemid 43922623)
23. Daenen S, Muskiet FA, Marrink J and Halie MR: Aggressive chemotherapy for acute leukaemia frequently causes intestinal protein leakage. Eur J Cancer 27: 552-556, 1991.
24. Nohria A, Prsic A, Liu PY, et al: Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis 205: 517-521, 2009.
25. Yeung VT, Ho SK, Cockram CS, Lee CM and Nicholls MG: C-type natriuretic peptide is a potent stimulator of cyclic GMP production in cultured mouse astrocytes. J Neurochem 59: 762-764, 1992.
26. Booth RF, Martin JF, Honey AC, Hassall DG, Beesley JE and Moncada S: Rapid development of atherosclerotic lesions in the rabbit carotid artery induced by perivascular manipulation. Atherosclerosis 76: 257-268, 1989. (Pubitemid 19101045)
27. Akishita M, Ouchi Y, Miyoshi H, et al: Estrogen inhibits cuff-induced intimal thickening of rat femoral artery: effects on migration and proliferation of vascular smooth muscle cells. Atherosclerosis 130: 1-10, 1997. (Pubitemid 27158023)
28. Moroi M, Zhang L, Yasuda T, et al: Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice. J Clin Invest 101: 1225-1232, 1998. (Pubitemid 28145238)
29. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362: 801-809, 1993.
30. Raval M, Frank PG, Laury-Kleintop L, Yan G and Lanza-Jacoby S: Celecoxib combined with atorvastatin prevents progression of atherosclerosis. J Surg Res 163: e113-e122, 2010.
31. Gaspari TA, Barber MN, Woods RL and Dusting GJ: Type-C natriuretic peptide prevents development of experimental atherosclerosis in rabbits. Clin Exp Pharmacol Physiol 27: 653-655, 2000. (Pubitemid 30436209)
32. Porreca E, Di Febbo C, Baccante G, Di Nisio M and Cuccurullo F: Increased transforming growth factor-beta(1) circulating levels and production in human monocytes after 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase inhibition with pravastatin. J Am Coll Cardiol 39: 1752-1757, 2002. (Pubitemid 34595284)
33. Rodriguez-Vita J, Sanchez-Galan E, Santamaria B, et al: Essential role of TGF-beta/Smad pathway on statin-dependent vascular smooth muscle cell regulation. PLoS One 3: e3959, 2008.